Scarica l'app Stockscreener
3.29
0.30%
-0.010
Pre-mercato:
3.31
0.02
+0.61%
Precedente Chiudi:
$3.30
Aprire:
$3.34
Volume 24 ore:
1.37M
Relative Volume:
0.56
Capitalizzazione di mercato:
$314.85M
Reddito:
-
Utile/perdita netta:
$-84.23M
Rapporto P/E:
-3.5618
EPS:
-0.9237
Flusso di cassa netto:
$-77.15M
1 W Prestazione:
+7.17%
1M Prestazione:
+5.45%
6M Prestazione:
-64.81%
1 anno Prestazione:
-20.15%
Intervallo 1D:
$3.2101
$3.385
Intervallo di 1 settimana:
$3.03
$3.54
Portata 52W:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
3.29 | 314.85M | 0 | -84.23M | -77.15M | -0.9237 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-25 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-12-11 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-12-11 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-08-27 | Iniziato | Guggenheim | Buy |
| 2024-07-17 | Iniziato | BTIG Research | Buy |
| 2024-06-04 | Iniziato | Craig Hallum | Buy |
| 2024-04-09 | Iniziato | Maxim Group | Buy |
| 2022-08-02 | Ripresa | Canaccord Genuity | Buy |
| 2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Iniziato | ROTH Capital | Buy |
| 2021-05-27 | Iniziato | Oppenheimer | Outperform |
| 2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute Announces Positive Phase 3 sunRIZE Results for Ersodetug in Congenital Hyperinsulinism, Shows Significant Glycemic Improvements and FDA Progress 1234 - Minichart
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA - TipRanks
Phase 3 sunRIZE miss but strong CGM gains for Rezolute (NASDAQ: RZLT) - Stock Titan
H.C. Wainwright reiterates Rezolute stock rating on CGM data By Investing.com - Investing.com Australia
Rezolute (RZLT) Presents Positive Findings from Phase 3 sunRIZE Study - GuruFocus
Rezolute presents expanded Phase 3 data for hyperinsulinism drug By Investing.com - Investing.com South Africa
Rezolute presents expanded Phase 3 data for hyperinsulinism drug - Investing.com
Rezolute, Inc. Reports Positive Continuous Glucose Monitoring Outcomes for Ersodetug in Phase 3 sunRIZE Study of Congenital Hyperinsulinism - Quiver Quantitative
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in ... - Caledonian Record
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout - MSN
Rezolute shares in focus after RA Capital discloses 9.9% stake - MSN
Rezolute, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
RZLT (Rezolute Inc.) drops 2.26% after Q1 2026 earnings report reveals wider than expected per-share loss. - Xã Vĩnh Công
RZLT (Rezolute Inc.) reports wider than expected Q1 2026 loss, shares edge higher even as earnings miss analyst estimates.High Volatility - UBND thành phố Hải Phòng
Rezolute (RZLT) Top Gainer | Q1 2026: Earnings UnderperformRegulatory Risk - Cổng thông tin điện tử tỉnh Lào Cai
Rezolute gains after positive FDA meeting over lead asset - MSN
Xoma Royalty Corporation Investigated by the Portnoy Law Firm - GlobeNewswire
Rezolute to present Phase 3 ersodetug data at medical meeting By Investing.com - Investing.com Australia
Rezolute to present Phase 3 ersodetug data at medical meeting - Investing.com
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting - The Manila Times
NervGen Pharma Corp. (NGEN) - Minichart
Rezolute (RZLT) Stock Under Pressure (Investor Concern) 2026-04-20Popular Trader Picks - Cổng thông tin điện tử Tỉnh Sơn La
Free cash flow per share of Rezolute, Inc. – MUN:6HV1 - TradingView
Rezolute (RZLT) Stock: Valuation Gap (-2.26%) 2026-04-18Correlation Analysis - Cổng thông tin điện tử tỉnh Tây Ninh
Rezolute, Inc. (NASDAQ:RZLT) Short Interest Down 21.2% in March - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Hold" by Brokerages - MarketBeat
Rezolute: Caught Between Biology And Statistics, Initiating With Hold Rating (NASDAQ:RZLT) - Seeking Alpha
FDA flexibility isn’t absent but evolving regulations come with growing pains - BioSpace
Rezolute’s Phase 3 SunRIZE study for Ersodetug fails to meet primary and secondary endpoints despite analyst backing - MSN
Rezolute Insider Confidence Rewarded, Stock Hits US$379m Market Cap - simplywall.st
Risk On: Is Rezolute Inc a top pick in the sectorFed Meeting & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Price Action: Will Rezolute Inc stock go up in YEARDollar Strength & Weekly Market Pulse Updates - baoquankhu1.vn
RZLT Q2 2026 Earnings: Rezolute Inc. posts wider-than-expected loss, reports no revenue - Cổng thông tin điện tử Tỉnh Sơn La
Rezolute stock gains after FDA meeting on Ersodetug program update - MSN
RZLT.O PE Ratio & Valuation, Is RZLT.O Overvalued - Intellectia AI
RZLT Technical Analysis & Stock Price Forecast - Intellectia AI
Rezolute, Inc. (RZLT) stock price, news, quote and history - Yahoo Finance UK
What is HC Wainwright's Estimate for Rezolute Q1 Earnings? - MarketBeat
Rezolute CFO Evans Daron buys $28,500 in RZLT stock By Investing.com - Investing.com South Africa
Rezolute CFO Evans Daron buys $28,500 in RZLT stock - Investing.com
Rezolute (RZLT) CFO adds 10,000 shares in open-market purchase - Stock Titan
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart - Capital.com
Rezolute Inc (RZLT) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rezolute Inc Azioni (RZLT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hogenhuis Wladimir | Director |
Dec 16 '25 |
Buy |
1.69 |
5,650 |
9,548 |
119,675 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Dec 16 '25 |
Buy |
1.70 |
28,000 |
47,600 |
308,352 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.77 |
40,000 |
70,640 |
415,900 |
| Evans Daron | CFO |
Dec 15 '25 |
Buy |
1.79 |
5,000 |
8,938 |
7,000 |
| Elam Nevan C | CEO |
Dec 15 '25 |
Buy |
1.59 |
32,000 |
50,880 |
641,119 |
| Karnawat Sunil Ratilal | Chief Commercial Officer |
Dec 15 '25 |
Buy |
1.62 |
12,100 |
19,599 |
71,542 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer |
Jun 25 '25 |
Buy |
4.38 |
2,500 |
10,939 |
15,500 |
| Evans Daron | CFO |
Jun 24 '25 |
Buy |
4.05 |
5,000 |
20,250 |
268,900 |
| Kim Young-Jin | Director |
Jun 13 '25 |
Buy |
3.25 |
1,230,769 |
3,999,999 |
8,423,386 |
| KREHER NERISSA | Director |
Jun 13 '25 |
Buy |
3.25 |
3,076 |
9,997 |
37,576 |
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):